The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.
Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.
A new analysis finds most cancer deaths that occur in people younger than 70 could be prevented. But biostatisticians not involved in the research urged caution in interpreting the data.